Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: Lp(a) and ASCVD: Translating Causal Evidence into Clinical Practice
Author(s): Michelle O'Donoghue Added: 1 month ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to… View more

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
CIRSE 25: The BIONETIC-I Study
Author(s): Marianne Brodmann Added: 2 months ago
CIRSE Congress 2025 - 24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.Prof Marianne Brodmann (Medical University of Graz, Graz, AT) joins us to discuss 24-month findings from BIONETIC-I (NCT04830228). The prospective, international, multi-center, single-arm study aimed to investigate the safety and effectiveness of… View more

Intervention

Vascular Disease and Surgery
The Hybrid Approach in CAD with Restore® DEB
Author(s): Alfonso Ielasi Added: 1 year ago
In this comprehensive video series, Dr Alfonso Ielasi (IRCCS Ospedale Galeazzi Sant'Ambrogio, IT) delves into the approach of using Restore® Drug-Eluting Balloon (DEB) in treating Coronary Artery Disease (CAD). View more

Intervention
NY Valves 25: Early Clinical and QoL Outcomes of the PASCAL System
Author(s): Santiago Garcia Added: 5 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings… View more

Intervention
NY Valves 25: The Tri-QOL Study
Author(s): Added: 5 months ago
New York Valves 25 - Quantitative findings from Tri-QOL showed a strong correlation between tricuspid regurgitation (TR) reduction and KCCQ improvement after transcatheter tricuspid valve intervention (TTVI).Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, Kansas City, US) discusses findings from a quantitative analysis from the Tri-QOL study which aimed to assess the optimal result… View more

Intervention
The FISH&CHIPS Study: Real-world Study Reveals Significant Reduction in All-cause and Cardiovascular Mortality
Author(s): Jonathon A Leipsic Added: 2 years ago
FISH&CHIPS two-year key outcomes associated with availability of FFRCT include:A significant 14% relative reduction in cardiovascular mortality and a significant 8% relative reduction in all-cause mortality.An increase in cath lab efficiency, driven by a 5% relative reduction in invasive cardiac angiography (ICA) and an 8% relative increase in Percutaneous Coronary Intervention (PCI).A 14%… View more

Guidelines & Statements

Imaging & Diagnostics
EuroPCR 25: The TRICURE EU Study
Author(s): Julien Dreyfus Added: 6 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating… View more

Intervention
LINC 2025: The EAGLE-Study
Author(s): Naoki Hayakawa Added: 9 months ago
LINC 2025 - Three-year outcomes of drug-coated balloon (DCB) treatment for femoropopliteal (FP) chronic total occlusive (CTO) lesions show low patency rates in patents with multiple independent risk factors for patency loss. However, patients without risk factors achieved acceptable patency rates and clinical outcomes of freedom from clinically driven target lesion revascularization, reoclussion… View more

Intervention

Vascular Disease and Surgery
LINC 25: The GRIFFIN Study
Author(s): Tatsuya Nakama Added: 10 months ago
LINC 2025 - Outcomes from the GRIFFIN study suggest post-procedural functional flow reserve (FFR) could be a useful predictor of restenosis after drug-coated balloon (DCB) angioplasty for superficial femoral artery (SFA) lesions. Restenosis patients showed significantly lower FFR values than non-restenosis patients, and the study resulted in a good FFR cut-off value of restenosis after DCB… View more

Intervention

Vascular Disease and Surgery
London Valves 25: AltaValve EFS: Broad Applicability at One-Year Outcomes
Author(s): Vlasis Ninios Added: 3 weeks ago
PCR London Valves 2025 - Dr Vlasis Ninios (Interbalkan European Medical Center, GR) discusses one-year outcomes from the AltaValve Early Feasibility Study, evaluating a novel atrial fixation system for transcatheter mitral valve replacement in patients with severe mitral regurgitation.This prospective, single-arm, multicenter study enrolled high surgical risk patients with moderate to severe or… View more

Intervention